|Symbols||; MAPKKK3; MEKK3|
|External IDs||IUPHAR: ChEMBL: GeneCards:|
|RNA expression pattern|
|File:PBB GE MAP3K3 203514 at tn.png|
This gene product is a 626-amino acid polypeptide that is 96.5% identical to mouse MEKK3. Its catalytic domain is closely related to those of several other kinases, including mouse MEKK2, tobacco NPK, and yeast STE11. Northern blot analysis revealed a 4.6-kb transcript that appears to be ubiquitously expressed.
MAP3Ks are involved in regulating cell fate in response to external stimuli. MAP3K3 directly regulates the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by activating SEK and MEK1/2 respectively. In cotransfection assays, it enhanced transcription from a nuclear factor kappa-B (NFKB)-dependent reporter gene, consistent with a role in the SAPK pathway. Alternatively spliced transcript variants encoding distinct isoforms have been observed. MEKK3 regulates the p38, JNK and ERK1/2 pathways.
MAP3K3 in cancer
Many studies have described the association of MAP3K3 (or MEKK3) in cancer.
Two SNPs in the MAP3K3 gene were found as candidates for association with colon and rectal cancers.
MEKK3 is highly expressed in 4 ovarian cancer cell lines (OVCA429, Hey, DOV13, and SKOv3). This expression level is significantly higher in those cancer cells when compared to normal cells. MEKK3 expression levels are comparable to IKK kinase activities, which also relate to activation of NFκB. High expression of MEKK3 in most of these ovarian cancer cells supposedly activate IKK kinase activity, which lead to increased levels of active NFκB. Also, MEKK3 interacts with AKT to activate NFκB. Genes related to cell survival and anti-apoptosis have increased expression in most cancer cells with high levels of MEKK3. This is probably due to constitutive activation of NFκB, which will regulate those genes. In this sense, knockdown of MEKK3 caused ovarian cancer cells to be more sensitive to drugs.
MEKK3 also interacts with BRCA1. Knocking down BRCA1 resulted in inhibited MEKK3 kinase activity. The drug paclitaxel induces MEKK3 activity and it requires functional BRCA1 to do it. It was observed that in a breast cancer cell line BRCA1-deficient (HCC1937), paclitaxel was unable to activate MEKK3. Paclitaxel may be inducing stress-response through the MEKK3/JNK/p38/MAPK pathway, but not in mutated BRCA1 cells.
Normal endothelial cells, but deficient in MEKK3, have reduced cell proliferation and increased apoptosis. MEKK3-deficient tumors, on the other hand, can grow in the same rate as regular tumors, also producing comparable levels of VEGF and inducing angiogenesis comparably to wild-type tumors. While these results show that MEKK3 is important for normal endothelial cells, MEKK3 may not be necessary for tumor growth and angiogenesis.
MEKK3 expression level is also significantly higher in cervical cancer in comparison with chronic cervicitis and CIN (cervical intraepithelial neoplasia). This high expression correlates with the also high levels of survivin (apoptosis inhibitor), and they both may associate with cervical cancer development and prognosis. Cao et al. suggest a targeted therapy of MEKK3 together with a therapy that promotes apoptosis as a possible new strategy for treatment of chemotherapeutic-resistant tumors.
Similarly, significantly higher levels of MEKK3 was found as well in esophageal dysplasia and esophageal squamous cell carcinoma (ESCC) when compared to normal esophageal tissue. MEKK3 seems to accumulate even more in ESCC than esophageal dysplasia, which also correlates with poor prognosis of ESCC. Therefore, MEKK3 can be studied for its possible role as an early biomarker of esophageal tumorigenesis.
From all these studies, MEKK3 has become a valuable target for the development of new cancer therapies and diagnosis/prognosis tools.
- Ellinger-Ziegelbauer H, Brown K, Kelly K, Siebenlist U (March 1997). "Direct activation of the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by an inducible mitogen-activated protein Kinase/ERK kinase kinase 3 (MEKK) derivative". J Biol Chem 272 (5): 2668–74. PMID 9006902. doi:10.1074/jbc.272.5.2668.
- MAP3K3 in GeneCards - The Human Gene Compendium. http://www.genecards.org/cgi-bin/carddisp.pl?gene=MAP3K3
- Craig EA, Stevens MV, Vaillancourt RR, et al (2008). MAP3Ks as central regulators of cell fate during development. Developmental Dynamics, 237, 3102-14.
- "Entrez Gene: MAP3K3 mitogen-activated protein kinase kinase kinase 3".
- Sun, W; Kesavan K; Schaefer B C; Garrington T P; Ware M; Johnson N L; Gelfand E W; Johnson G L (February 2001). "MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway". J. Biol. Chem. (United States) 276 (7): 5093–100. ISSN 0021-9258. PMID 11073940. doi:10.1074/jbc.M003719200.
- Bouwmeester, Tewis; Bauch Angela, Ruffner Heinz, Angrand Pierre-Olivier, Bergamini Giovanna, Croughton Karen, Cruciat Cristina, Eberhard Dirk, Gagneur Julien, Ghidelli Sonja, Hopf Carsten, Huhse Bettina, Mangano Raffaella, Michon Anne-Marie, Schirle Markus, Schlegl Judith, Schwab Markus, Stein Martin A, Bauer Andreas, Casari Georg, Drewes Gerard, Gavin Anne-Claude, Jackson David B, Joberty Gerard, Neubauer Gitte, Rick Jens, Kuster Bernhard, Superti-Furga Giulio (February 2004). "A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway". Nat. Cell Biol. (England) 6 (2): 97–105. ISSN 1465-7392. PMID 14743216. doi:10.1038/ncb1086.
- Fanger, G R; Widmann C; Porter A C; Sather S; Johnson G L; Vaillancourt R R (February 1998). "14-3-3 proteins interact with specific MEK kinases". J. Biol. Chem. (UNITED STATES) 273 (6): 3476–83. ISSN 0021-9258. PMID 9452471. doi:10.1074/jbc.273.6.3476.
- Che, Wenyi; Lerner-Marmarosh Nicole, Huang Qunhua, Osawa Masaki, Ohta Shinsuke, Yoshizumi Masanori, Glassman Michael, Lee Jiing-Dwan, Yan Chen, Berk Bradford C, Abe Jun-Ichi (June 2002). "Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression". Circ. Res. (United States) 90 (11): 1222–30. PMID 12065326. doi:10.1161/01.RES.0000021127.83364.7D.
- Gilmore, Paula M; McCabe Nuala, Quinn Jennifer E, Kennedy Richard D, Gorski Julia J, Andrews Heather N, McWilliams Stewart, Carty Michael, Mullan Paul B, Duprex W Paul, Liu Edison T, Johnston Patrick G, Harkin D Paul (June 2004). "BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3". Cancer Res. (United States) 64 (12): 4148–54. ISSN 0008-5472. PMID 15205325. doi:10.1158/0008-5472.CAN-03-4080.
- Samanta AK, Huang HJ, Le XF, et al (2009). MEKK3 expression correlates with nuclear factor kappa B activity and with expression of anti-apoptotic genes in serous ovarian carcinoma. Cancer, 115, 3897-908.
- Slattery ML, Lundgreen A, Wolff RK (2012). MAP kinase genes and colon and rectal cancer. Carcinogenesis, 33(12), 2398-408.
- Deng Y, Yang J, McCarty M, et al (2007). MEKK3 is required for endothelium function but is not essential for tumor growth and angiogenesis. Am J Physiol Cell Physiol, 293, 1404-11.
- Cao XQ, Lu HS, Zhang L, Chen LL, Gan MF (2014). MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis. Asian Pac J Cancer Prev., 15(13), 5271-6
- Hasan R, Sharma R, Saraya A, et al (2014). Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis. BMC Cancer, 14, 2.
- Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.". Gene 138 (1-2): 171–4. PMID 8125298. doi:10.1016/0378-1119(94)90802-8.
- Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery.". Genome Res. 6 (9): 791–806. PMID 8889548. doi:10.1101/gr.6.9.791.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library.". Gene 200 (1-2): 149–56. PMID 9373149. doi:10.1016/S0378-1119(97)00411-3.
- Fanger GR, Widmann C, Porter AC et al. (1998). "14-3-3 proteins interact with specific MEK kinases.". J. Biol. Chem. 273 (6): 3476–83. PMID 9452471. doi:10.1074/jbc.273.6.3476.
- Chao TH, Hayashi M, Tapping RI et al. (2000). "MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway.". J. Biol. Chem. 274 (51): 36035–8. PMID 10593883. doi:10.1074/jbc.274.51.36035.
- Yang J, Boerm M, McCarty M et al. (2000). "Mekk3 is essential for early embryonic cardiovascular development.". Nat. Genet. 24 (3): 309–13. PMID 10700190. doi:10.1038/73550.
- Sun W, Kesavan K, Schaefer BC et al. (2001). "MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway.". J. Biol. Chem. 276 (7): 5093–100. PMID 11073940. doi:10.1074/jbc.M003719200.
- Hartley JL, Temple GF, Brasch MA (2001). "DNA cloning using in vitro site-specific recombination.". Genome Res. 10 (11): 1788–95. PMC 310948. PMID 11076863. doi:10.1101/gr.143000.
- Wiemann S, Weil B, Wellenreuther R et al. (2001). "Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs.". Genome Res. 11 (3): 422–35. PMC 311072. PMID 11230166. doi:10.1101/gr.GR1547R.
- Simpson JC, Wellenreuther R, Poustka A et al. (2001). "Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing.". EMBO Rep. 1 (3): 287–92. PMC 1083732. PMID 11256614. doi:10.1093/embo-reports/kvd058.
- Yang J, Lin Y, Guo Z et al. (2001). "The essential role of MEKK3 in TNF-induced NF-kappaB activation.". Nat. Immunol. 2 (7): 620–4. PMID 11429546. doi:10.1038/89769.
- Che W, Lerner-Marmarosh N, Huang Q et al. (2002). "Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression.". Circ. Res. 90 (11): 1222–30. PMID 12065326. doi:10.1161/01.RES.0000021127.83364.7D.
- Lee CM, Onésime D, Reddy CD et al. (2002). "JLP: A scaffolding protein that tethers JNK/p38MAPK signaling modules and transcription factors.". Proc. Natl. Acad. Sci. U.S.A. 99 (22): 14189–94. PMC 137859. PMID 12391307. doi:10.1073/pnas.232310199.
- Adams DG, Sachs NA, Vaillancourt RR (2002). "Phosphorylation of the stress-activated protein kinase, MEKK3, at serine 166.". Arch. Biochem. Biophys. 407 (1): 103–16. PMID 12392720. doi:10.1016/S0003-9861(02)00464-2.
- Strausberg RL, Feingold EA, Grouse LH et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. PMC 139241. PMID 12477932. doi:10.1073/pnas.242603899.
- Matsuda A, Suzuki Y, Honda G et al. (2003). "Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways.". Oncogene 22 (21): 3307–18. PMID 12761501. doi:10.1038/sj.onc.1206406.
- Nakamura K, Johnson GL (2003). "PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway.". J. Biol. Chem. 278 (39): 36989–92. PMID 12912994. doi:10.1074/jbc.C300313200.
- Huang Q, Yang J, Lin Y et al. (2004). "Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3.". Nat. Immunol. 5 (1): 98–103. PMID 14661019. doi:10.1038/ni1014.
- Samanta AK, Huang HJ, Bast RC, Liao WS (2004). "Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.". J. Biol. Chem. 279 (9): 7576–83. PMID 14662759. doi:10.1074/jbc.M311659200.
- Stevens MV, Broka DM, Parker P, Rogowitz E, Vaillancourt RR, Camenisch TD (2008). "MEKK3 initiates Transforming Growth Factor beta 2-dependent epithelial-to-mesenchymal transition during endocardial cushion morphogenesis.". Circ. Res. 103 (12): 1430–1440. PMC 2728220. PMID 19008476. doi:10.1161/CIRCRESAHA.108.180752.